Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Brown-Forman Corporation Class B — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Brown-Forman Corporation Class B trades at $26.14. The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BF.B | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $31.26 |
52-Week Low | $278.09 | $22.80 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BF.B trades at $26.17, up 3.77% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings, reflecting cautious optimism amid weak valuation ratio data.
The stock faces headwinds from bearish technical trends and incomplete fundamental metrics, but consistent earnings beats provide a positive catalyst. Risks include market volatility and lack of recent news, while institutional sentiment remains divided. Upside depends on future financial disclosures confirming profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
